Dougherty & Co Comments on Semler Scientific Inc’s FY2018 Earnings (SMLR)

Semler Scientific Inc (OTCMKTS:SMLR) – Equities researchers at Dougherty & Co lifted their FY2018 EPS estimates for shares of Semler Scientific in a research note issued on Sunday, October 28th. Dougherty & Co analyst K. Bauser now forecasts that the medical equipment provider will earn $0.67 per share for the year, up from their prior forecast of $0.63. Dougherty & Co has a “Buy” rating and a $48.00 price target on the stock. Dougherty & Co also issued estimates for Semler Scientific’s Q4 2018 earnings at $0.19 EPS and FY2019 earnings at $0.94 EPS.

Semler Scientific (OTCMKTS:SMLR) last posted its quarterly earnings results on Friday, October 26th. The medical equipment provider reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.01. Semler Scientific had a negative return on equity of 299.31% and a net margin of 19.66%. The business had revenue of $5.58 million for the quarter, compared to analysts’ expectations of $5.88 million.

Separately, Lake Street Capital set a $40.00 price objective on Semler Scientific and gave the company a “buy” rating in a report on Monday.

SMLR opened at $32.50 on Wednesday. Semler Scientific has a 1-year low of $5.81 and a 1-year high of $40.00. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $198.93 million, a P/E ratio of -116.07, a price-to-earnings-growth ratio of 2.33 and a beta of 0.69.

In other Semler Scientific news, VP Daniel E. Conger sold 5,000 shares of the company’s stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $25.78, for a total value of $128,900.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 13.90% of the company’s stock.

Semler Scientific Company Profile

Semler Scientific, Inc develops, manufactures, and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the United States. Its products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition; and WellChec, a multi-test service platform to evaluate patients with various chronic diseases.

Further Reading: Does the discount rate affect the economy?

Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply